FLUI Stock Overview
Operates as a life science company, provides platforms and research solutions for bioprinting and single-cell biology. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Fluicell AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.05 |
| 52 Week High | SEK 0.54 |
| 52 Week Low | SEK 0.03 |
| Beta | 2.06 |
| 1 Month Change | 2.88% |
| 3 Month Change | -19.61% |
| 1 Year Change | -90.55% |
| 3 Year Change | -99.70% |
| 5 Year Change | -99.62% |
| Change since IPO | -99.67% |
Recent News & Updates
Shareholder Returns
| FLUI | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | -10.1% | -0.1% | 0.3% |
| 1Y | -90.5% | -0.04% | 13.5% |
Return vs Industry: FLUI underperformed the Swedish Medical Equipment industry which returned -0% over the past year.
Return vs Market: FLUI underperformed the Swedish Market which returned 12.6% over the past year.
Price Volatility
| FLUI volatility | |
|---|---|
| FLUI Average Weekly Movement | 24.1% |
| Medical Equipment Industry Average Movement | 7.9% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 12.2% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: FLUI's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: FLUI's weekly volatility has increased from 18% to 24% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 10 | Carolina Trjulja | www.fluicell.com |
Fluicell AB (publ) operates as a life science company, provides platforms and research solutions for bioprinting and single-cell biology. The company offers BIOPEN, a microfluidic platform for high-precision single-cell solution delivery that enables to control the cell microenvironment without moving or disturbing the cells; Biozone 6 that generate dose-response curves or study the effects of multiple drug compounds; and Dynaflow Resolve system, an ion channel screening platform, which allows to record various ion channel current in patch-clamp recording configuration. It also provides Biopixlar, a 3D single-cell bioprinting platform that enables high cell viability and cell-to-cell communication; and Biopixlar AER, an easy-to-use 3D bioprinting platform that fits into your fume hood or biosafety cabinet.
Fluicell AB (publ) Fundamentals Summary
| FLUI fundamental statistics | |
|---|---|
| Market cap | SEK 24.04m |
| Earnings (TTM) | -SEK 22.14m |
| Revenue (TTM) | SEK 1.56m |
15.4x
P/S Ratio-1.1x
P/E RatioIs FLUI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FLUI income statement (TTM) | |
|---|---|
| Revenue | SEK 1.56m |
| Cost of Revenue | SEK 1.45m |
| Gross Profit | SEK 103.00k |
| Other Expenses | SEK 22.24m |
| Earnings | -SEK 22.14m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 21, 2025
| Earnings per share (EPS) | -0.046 |
| Gross Margin | 6.62% |
| Net Profit Margin | -1,422.88% |
| Debt/Equity Ratio | 0% |
How did FLUI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/06 14:57 |
| End of Day Share Price | 2025/02/06 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Fluicell AB (publ) is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.